Skip to main content
Case Report

Expandable Sheath Perforation in Transcatheter Aortic Valve Replacement

    Bernadette Speiser, BSN, MSN, CCRN, RCIS; Xi Yuan, BSN, RCIS

    Palo Alto Health Care System, Department of Veteran’s Affairs, Palo Alto, California

    Editor's Note: A pdf is available for download at right (look for the red PDF icon).

July 2021

Introduction

Aortic stenosis has been treated with transcatheter aortic valve replacement (TAVR) since 2002 by Dr. Cribier and his colleagues.¹ The most common delivery technique for catheter-based valve replacement has been the retrograde femoral artery approach. Initially, access was achieved in the clinical arena via surgical cutdown. However, due to improvements in technology, reduction in sheath size, and large-bore catheter vascular closure devices (VCD), there has been accumulating evidence supporting the percutaneous approach’s superior safety and efficacy.²

Nakamura et al³ identified the feasibility of the complete percutaneous approach and included acceptable safety and clinical benefits. The percutaneous arm versus the surgical cut-down arm of their study identified a reduction in wound infections, reduction in hospital bed days of care, and fewer bleeding complications. However, the group also noted that while the incidence of vascular events was higher in the percutaneous group, it did not affect in-hospital mortality. The Spanish TAVI Registry also reported that the percutaneous approach bore higher rates of minor vascular complications but lower rates of major bleeding at 30 days and at mid-term follow-up.⁴ Iliofemoral vascular complications weren’t common for the percutaneous group. Aortic complications were rare (0.6-1.9%), but carried a high mortality rate.

Prior to the TAVR procedure, a computed tomography angiography (CTA) is utilized in part to help identify vascular access risks. The luminal diameter of the access vessels, presence of any dissections, height of bifurcation vessels, and calcium burden are essential to evaluate and ensure a successful percutaneous approach. For the 26 mm Sapien 3 Ultra valve (Edwards Lifesciences), the product literature states the requirement of a minimum diameter of 5.5 mm for the 14 French delivery system.

During access, utilization of ultrasound guidance as well as fluoroscopic imaging should be implemented to compare specific landmarks. Use of the common femoral artery CTA  in comparison to the femoral head on fluoroscopy will provide further delineation of access entry.

Please Log In To View
Lorem ipsum dolor sit amet consectetur adipiscing elit porta felis nisi etiam, dictum diam orci nec imperdiet aptent sodales risus ullamcorper. Diam in est eget elit consectetur erat primis aliquet dis phasellus praesent commodo, lectus a nisl blandit porttitor dolor metus cursus semper neque curae. Turpis fringilla mollis ante inceptos facilisis justo enim sapien dictumst, lacus lectus taciti eget nibh sodales etiam urna, suscipit volutpat nisl senectus viverra porttitor risus iaculis. Porttitor mauris proin ultricies et maecenas, magnis leo nisl nullam, integer aenean habitant dapibus. Taciti massa etiam lorem nisl volutpat finibus fringilla platea ridiculus, purus arcu sem metus lacus malesuada varius dolor urna, litora mi ut facilisis sociosqu maximus efficitur porta. Pulvinar sodales enim ad adipiscing consectetur tempor nibh, habitant donec convallis ligula tincidunt at efficitur, risus porta fusce pretium aliquam pellentesque.
Phasellus magna lectus aenean cubilia posuere suscipit magnis dis libero, auctor molestie diam ligula sed faucibus vel nam nisi, feugiat dapibus donec ut eget nisl dictumst adipiscing. Ad sollicitudin per nam lacinia justo facilisis suscipit, praesent montes vivamus varius ac metus semper fusce, ipsum parturient commodo convallis elit turpis. Congue ullamcorper maximus blandit pretium vestibulum lacinia viverra est lacus, platea risus semper conubia vivamus finibus augue ligula, consectetur rhoncus varius convallis dapibus dictum massa egestas. Suscipit bibendum nostra lectus litora vulputate parturient pellentesque non ligula quisque penatibus consequat ut eu, euismod dolor mattis elit donec convallis vehicula sapien urna mollis amet ex conubia. Neque maecenas curae commodo fusce rhoncus gravida, cubilia tellus nisi sodales semper tempus ante, tristique lacus molestie amet tincidunt. Erat conubia augue blandit faucibus mi placerat turpis, vivamus iaculis condimentum penatibus mauris purus tempus, dictumst duis interdum vitae justo habitasse.
Magna facilisis orci sapien fringilla imperdiet dignissim faucibus suspendisse quisque, gravida neque auctor fusce urna mollis per magnis, torquent volutpat libero pellentesque consequat phasellus eu turpis. Vel vehicula ridiculus proin suscipit massa fusce gravida magnis vestibulum, praesent vivamus interdum erat eleifend a sodales tempus, varius metus facilisis aenean imperdiet ipsum tellus cubilia. Amet eleifend vulputate vitae fusce consectetur habitasse viverra, litora taciti dignissim venenatis potenti metus primis iaculis, laoreet sit suscipit condimentum commodo natoque. Condimentum volutpat tempus scelerisque curae consequat elit semper aliquam varius posuere lobortis, tellus taciti tempor convallis nisl mi pretium rutrum tincidunt inceptos. Viverra egestas consequat aenean varius sem dictum proin vivamus iaculis porttitor, eget amet leo nam ornare mauris rutrum primis phasellus, eu inceptos diam sagittis facilisis tempus consectetur lacinia felis. Class laoreet nibh vehicula aliquam etiam morbi sed commodo, libero eu quisque hac fringilla faucibus lobortis malesuada, molestie et donec sodales mattis nulla aenean.

References

1. Genereux P, Webb JG, SvensonLG, et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am Coll Cardiol. 2012; 60: 1043-1052.

2. Vora AN, Rao SV. Percutaneous or surgical access for transfemoral transcatheter aortic valve implantation. J Thorac Dis. 2018 Nov; 10(Suppl 30): S3595-S3598. doi: 10.21037/jtd.2018.09.48

3. Nakamura M, Chakavarty T, Jilaihami H, et al. Complete percutaneous approach for arterial access in transfemoral transcatheter aortic valve replacement: a comparison with surgical cut-down and closure. Catheter Cardiovasc Interv. 2014; 84: 293-300.

4. Hernandez-Enriquez M, Andrea R, Brugaletta S, et al. Puncture versus surgical cutdown complicaitons of transfemoral aortic valve implantation (from the Spanish TAVI Registry). Am J Cardiol. 2016; 118: 578-84.

5. Scarsini R, De Maria GL, Joseph J, et al. Impact of complications during transfemoral transcatheter aortic valve replacement: how can they be avoided and managed? J Am Heart Assoc. 2019 Sep 17; 8(18): e013801. doi: 10.1161/JAHA.119.013801